237 related articles for article (PubMed ID: 29870189)
1. [Magnetic resonance imaging in the course of alemtuzumab and teriflunomide therapy].
Mike A; Kincses ZT; Vécsei L
Ideggyogy Sz; 2017 Jan; 70(1-2):15-24. PubMed ID: 29870189
[TBL] [Abstract][Full Text] [Related]
2. [Alemtuzumab and teriflunomide approved].
Fischer S
Med Monatsschr Pharm; 2013 Oct; 36(10):393-4. PubMed ID: 24266250
[No Abstract] [Full Text] [Related]
3. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on teriflunomide.
Tallantyre E; Evangelou N; Constantinescu CS
Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
[TBL] [Abstract][Full Text] [Related]
5. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
Miller AE
Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
[TBL] [Abstract][Full Text] [Related]
6. Teriflunomide in multiple sclerosis: an update.
Miller AE
Neurodegener Dis Manag; 2017 Feb; 7(1):9-29. PubMed ID: 27937746
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of action of three newly registered drugs for multiple sclerosis treatment.
Kasarełło K; Cudnoch-Jędrzejewska A; Członkowski A; Mirowska-Guzel D
Pharmacol Rep; 2017 Aug; 69(4):702-708. PubMed ID: 28550802
[TBL] [Abstract][Full Text] [Related]
8. Teriflunomide for the treatment of multiple sclerosis.
Warnke C; Stüve O; Kieseier BC
Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S90-4. PubMed ID: 24321165
[TBL] [Abstract][Full Text] [Related]
9. Teriflunomide for the treatment of multiple sclerosis.
Oh J; O'Connor PW
Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
[TBL] [Abstract][Full Text] [Related]
10. Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.
Frau J; Coghe G; Fenu G; Lorefice L; Cocco E
Neurol Sci; 2018 Feb; 39(2):389-390. PubMed ID: 28986705
[No Abstract] [Full Text] [Related]
11. Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
Yamout BI; Said M; Hannoun S; Zeineddine M; Massouh J; Khoury SJ
J Neurol Sci; 2017 Sep; 380():79-81. PubMed ID: 28870594
[TBL] [Abstract][Full Text] [Related]
12. Teriflunomide (Aubagio®) for the treatment of multiple sclerosis.
Bar-Or A
Exp Neurol; 2014 Dec; 262 Pt A():57-65. PubMed ID: 24925677
[TBL] [Abstract][Full Text] [Related]
13. [Teriflunomide (Aubagio). New treatment for multiple sclerosis].
Sabourin G
Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766
[No Abstract] [Full Text] [Related]
14. A case of acute fulminant multiple sclerosis treated with alemtuzumab.
Gobbin F; Marangi A; Orlandi R; Richelli S; Turatti M; Calabrese M; Forgione A; Alessandrini F; Benedetti MD; Monaco S; Gajofatto A
Mult Scler Relat Disord; 2017 Oct; 17():9-11. PubMed ID: 29055482
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of alemtuzumab in Korean multiple sclerosis patients.
Kim H; Lee EJ; Kim SK; Kim KK; Lim YM
Mult Scler Relat Disord; 2019 May; 30():247-251. PubMed ID: 30849681
[TBL] [Abstract][Full Text] [Related]
16. [Teriflunomide (Aubagio), oral administration].
J Pharm Belg; 2015 Sep; (3):49-55. PubMed ID: 26513836
[No Abstract] [Full Text] [Related]
17. Preapproval and postapproval evidence on drugs for multiple sclerosis.
Gerardi C; Bertele' V; Rossi S; Garattini S; Banzi R
Neurology; 2018 May; 90(21):964-973. PubMed ID: 29695598
[TBL] [Abstract][Full Text] [Related]
18. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Bencsik K; Rózsa C; Vécsei L
Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
[TBL] [Abstract][Full Text] [Related]
19. PML in a person with multiple sclerosis: Is teriflunomide the felon?
Lorefice L; Fenu G; Gerevini S; Frau J; Coghe G; Barracciu MA; Contu F; Marrosu MG; Cocco E
Neurology; 2018 Jan; 90(2):83-85. PubMed ID: 29212829
[No Abstract] [Full Text] [Related]
20. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
[No Abstract] [Full Text] [Related]
[Next] [New Search]
